Cambridge Healthtech Institute’s 15th Annual

Liquid Biopsy

Enabling Precision Oncology for Diagnostic and Drug Development

March 11-12, 2025

Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute’s 15th Annual Liquid Biopsy meeting will explore the latest technologies in detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA) and circulating extracellular RNA, exosomes, and microvesicles. Applications of liquid biopsy biomarkers in diagnostics and drug development, including minimal residual disease (or molecular residual disease, MRD), patient selection and treatment monitoring, and early cancer detection will be discussed.

Coverage will include, but is not limited to:

Cancer screening and early cancer detection
Liquid biopsy for minimal residual disease detection
Technology update in liquid biopsy detection and characterization
Applications of cell-free DNA and RNA as biomarkers in drug development
Liquid biopsy biomarkers for patient selection and treatment monitoring
Exosomes and microvesicles as biomarkers
Predicting immunotherapy response through circulating immune cells
Liquid biopsy for companion diagnostics

The deadline for priority consideration is September 13, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: